Furthermore, the syngeneic KP tumor models demonstrated that distinct subsets of lung cancer cells with varying baseline sensitivities to MEK inhibitor also developed resistance to double combination therapy, suggesting that a mutual factor promotes resistance. The gene discussed is MAP2K7; the disease is lung carcinoma.